Advertisement

Topics

Targovax Company Profile

13:44 EDT 18th June 2018 | BioPortfolio

Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 90’s. The drug has already been tested in patients, and the company is building on these results. The company is based in Lysaker close to Oslo, Norway, and co-located with Oslo Cancer Cluster.


News Articles [38 Associated News Articles listed on BioPortfolio]

Targovax (TRVX) - FOLFIRINOX sets bar in pancreatic cancer high

Edison Investment Research - Pharmaceutical & healthcare - Targovax: On 12 June, Targovax announced a strategic decision to move away from developing TG01, a neoantigen cancer vaccine for pancreatic c...

Targovax's Viral IO Therapy, Anticancer Vaccine Aimed At Combos

Targovax’s strategy is to use its products as immune response primers and combine them with other anticancer therapies, but the...    

Targovax ASA: Exercise price of options

With reference to the Stock exchange notification issued 1 February 2018 regarding options to employees: The exercise price of the granted options is NOK 17.17. The exercise price is eq...

Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program

Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its...   

Appointments: Hikma, Ipsen, PeptiDream, Targovax, Moderna and Perrigo

The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as...   

Targovax gives pipeline update

Targovax raises €21m in private placement

Targovax (TRVX) - Key catalysts in 2018

Edison Investment Research - Pharmaceutical & healthcare - Targovax: Q417 saw the release of several reports indicating a good safety profile and consistent immune activation signs by ONCOS-102, an on...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Targovax

Targovax was started in October 2010 to develop TG01, a vaccine targeting pancreatic cancer. TG01 is based on research from The Radium Hospital and Norsk Hydro in the end of the 9...

More Information about "Targovax" on BioPortfolio

We have published hundreds of Targovax news stories on BioPortfolio along with dozens of Targovax Clinical Trials and PubMed Articles about Targovax for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targovax Companies in our database. You can also find out about relevant Targovax Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record